Genprex Reports Positive Preclinical Data for GPX-002 Diabetes Gene Therapy in Animal Studies

summarizeSummary

Genprex announced positive preliminary preclinical data for its GPX-002 gene therapy in Type 2 diabetic animal models, demonstrating rejuvenation of beta cells and normalized glucose levels.

check_boxKey Events · Product Development and Regulatory · GNPX

• Positive Preclinical Data in T2D Non-Human Primates

  GPX-002 demonstrated in vivo proof-of-concept in Type 2 diabetic non-human primates, with one NHP achieving normal glucose tolerance testing at seven months following intraductal infusion, consistent with rejuvenated beta cells.

• Efficacy Demonstrated in T2D Mice

  Preclinical studies in Type 2 diabetic mice showed GPX-002 increased glucose stimulated insulin secretion, rejuvenated exhausted beta cells, reversed hyperglycemia, and normalized glucose levels without requiring immunosuppression.

• Potential for Long-Term Diabetes Control

  The data supports GPX-002's potential for long-term control of both Type 1 and Type 2 diabetes by either transforming alpha cells or rejuvenating exhausted beta cells, respectively. The company is planning formal toxicology studies and an IND submission.

auto_awesomeAnalysis · GNPX · Life Sciences

Genprex's announcement of positive preliminary preclinical data for GPX-002 in Type 2 diabetic animal models is a very important development for this micro-cap biotechnology company. Demonstrating in vivo proof-of-concept in non-human primates and rejuvenating exhausted beta cells in mice provides significant validation for their novel gene therapy approach. This data strengthens the potential of GPX-002 to offer long-term control for both Type 1 and Type 2 diabetes, a massive unmet medical need. The company's plans for formal toxicology studies and an Investigational New Drug (IND) submission indicate a clear path forward, which could be a major catalyst for future funding and partnerships.